Computed tomography and magnetic resonance imaging findings of ureteral myxedema in Graves’ disease

Minutoli, Fabio; Benedetto, Caterina; Visalli, Carmela; Granata, Antonio; Gaeta, Michele

doi:10.1016/j.clinimag.2015.02.012

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 8 – 10 In addition, buttock nodules and ureteral myxedema have been reported in patients with GD. 11 , 12 PTM patients with mild condition are usually asymptomatic, but severe cases may induce functional problems such as difficulty in dressing and wearing socks and shoes. Only few patients could have painful, pruritic, and hyperpigmentation conditions.…”

Section: Introductionmentioning

confidence: 99%

Treatment of pretibial myxedema with intralesional immunomodulating therapy

Ren

Deng

et al. 2017

TCRM

View full text Add to dashboard Cite

ObjectiveLocal immune regulation therapy has been one of the therapeutic methods used for the treatment of autoimmune thyroid disease in patients with pretibial myxedema (PTM). However, the poor response rate and high recurrence rate are still major problems. Whether a premixed corticosteroid, compound betamethasone, could enhance remission rate and decrease recurrence rate in patients with PTM was investigated in the present study.Subjects and methodsWe have performed a clinical utility observation of compound betamethasone with intralesional injections based on basic thyroid disease treatment in 32 PTM patients between January 2008 and August 2016. The patients were followed up for 2 years, and the clinical outcomes and side effects were calculated and analyzed.ResultsAll patients had a complete remission after different times of injection. A total of 21.7% patients had complete remission with one time of injection, 34.8% with two times of injection, 17.4% with three times of injection, 4.3% with four times of injection, and 4.3% with five times of injection. In all, 56.3% patients with a disease duration of <6 months had complete remission after a 1-month treatment, 37.5% patients with a disease duration between 6 months and 12 months had complete remission after a 2-month treatment, 3.1% patients with a disease duration of 2 years had complete remission after a 5-month treatment, and 3.1% with a disease duration of 5 years had complete remission after a 7-month treatment.ConclusionCompound betamethasone with multipoint intralesional injection is a feasible, effective, and secure novel strategy in the treatment of PTM.

show abstract